Episode 272: ESMO 2023: EV-302 and CM901 in First-line Bladder Cancer

Michiel Van der Heijdan, MD, PhD, discusses EV-302 and CheckMate-901 on enfortumab veodtin plus pembrolizumab and nivolumab plus ipilimumab for metastatic urothelial carcinoma.

Dr. Van der Heijden is a medical oncologist research group leader at The Netherlands Cancer Institute, focusing on the improvement of bladder cancer treatment.